Will Anthropic’s IPO be delayed, or will the price be lowered?

The short answer is that a delay is a real possibility, though nothing has been announced yet. Based on reports, a lower price or a smaller IPO size is the more likely initial outcome, with a potential shift to December remaining a key risk.

On Thursday, the Nasdaq 100 fell by 6.4%, wiping out $2.3 trillion in market capitalization in a single session—a record for a one-day decline. This drop directly impacts the pricing process for a company like Anthropic that is preparing for an IPO, as investor appetite can shift rapidly within the span of a single day.

What is being discussed at the negotiating table?

According to Bloomberg, potential buyers are discussing a valuation range of $1.2 trillion to $1.3 trillion, down from the previously discussed $1.4 trillion to $1.5 trillion. The Wall Street Journal reports that three major participating investors have indicated that the valuation will need to be lowered, with one suggesting a figure closer to $1 trillion. One investor noted that the size of the IPO might be around $80 billion, rather than the planned $100 billion.

Anthropic had been aiming to launch its IPO during the week before Thanksgiving, under the ticker symbol "ANT." In other words, the timeline remains on the table, but the price range is being revised.

How credible is the $1.1 trillion floor and other such claims?

One should exercise caution regarding verification. The sources cited for the $1.1 trillion floor claim actually point to a figure closer to $1 trillion—not $1.1 trillion. There has been no independent confirmation of the approximately $1.6 trillion valuation—or the roughly $340 billion decline—implied on Hyperliquid. Furthermore, the existence of speculative crypto-based futures for a company prior to its initial public offering (IPO) is, in itself, a weak signal.

As for claims regarding slowing revenue and operating losses, the figures from the S-1 filing have yet to be seen. While a news headline may mention slowing revenue, this does not constitute a formal financial statement; until confirmed, such claims should be treated merely as allegations.

What is the argument against a delay?

Pricing is not a trigger for cancellation, but rather a matter of negotiation. Analysts speaking to Bloomberg suggest that a valuation near $1.2 trillion should not prevent Anthropic from securing investors. Even at a lower price point, the valuation would remain significantly above the $965 billion figure reached during the Series H round in May.

In other words, the company could simply lower its valuation and proceed. A market downturn does not automatically shelve an IPO; it merely makes the offering less expensive.

What is the argument in favor of a delay?

Prediction markets are betting on a listing in December. A record single-day decline complicates the book-building process. A strategist at one bank suggested that a valuation closer to $1 trillion might be safer, as it would reduce the risk of sharp volatility once trading begins.

Crucially, however, there has been no confirmed report that the IPO has been delayed or canceled. The "roadshow" cannot begin before approximately November 10, so the next few days will serve as the real test.

There are five signals to watch; the first is the filing of a price range or an update to the S-1. The second is whether the roadshow begins according to the scheduled timeline. The third factor is whether the Nasdaq 100 has stabilized or if the sell-off is continuing. The fourth is any change in the size of the planned initial public offering (IPO). The fifth is how the political scrutiny surrounding data centers—mentioned in the headlines—plays out.

What could shift this outlook? A recovery in AI-related stocks would make pricing before Thanksgiving more likely. Conversely, a second wave of declines or a downward revision in guidance would make a timeline of December or later more probable.

What is the lesson for the individual investor?

This story is not just about the IPO of a single company; it is a test of the relationship between valuation and liquidity. When the broader market falls, even high-quality companies see their valuations drop—but becoming cheaper does not mean ceasing to exist.

In practical terms, you should monitor whether it is the price or the timeline that changes. A change in price is a standard part of the negotiation process, whereas a change in the timeline serves as a stronger signal that demand may be weakening. Rather than conflating the two, it is essential to focus on concrete developments, such as updates to the S-1 filing or changes in company guidance.

This content is for informational purposes only and does not constitute investment advice.

#Gate股票畅聊季 #GateStockTalkSeason #ShareWeekly #USAIStocksHitHard

$US500 $US30 $NAS100